Advanced search
Publication Cover
Pharmacogenomics Volume 12, 2011 - Issue 7
Submit an article Journal homepage
2,439
Views
0
CrossRef citations to date
0
Altmetric
Review

Transporter-Mediated Drug–Drug Interactions

Fabian Müller1 Institute of Experimental & Clinical Pharmacology & Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany.View further author information
&
Martin F Fromm1 Institute of Experimental & Clinical Pharmacology & Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany.;2 Tel.:+49 9131 85 22772 Fax: +49 9131 85 [email protected]View further author information
Pages 1017-1037 | Published online: 25 Jul 2011

Bibliography

  • Ho RH , KimRB. Transporters and drug therapy: Implications for drug disposition and disease. Clin. Pharmacol. Ther.78(3) , 260–277 (2005).
  • Shitara Y , SatoH, SugiyamaY. Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol.45 , 689–723 (2005).
  • Girennavar B , JayaprakashaGK, PatilBS. Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins. J. Food Sci.72(8) , C417–C421 (2007).
  • Bressler R . Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics61(11) , 12–18 (2006).
  • Dresser GK , BaileyDG, LeakeBF et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71(1) , 11–20 (2002).
  • Cvetkovic M , LeakeB, FrommMF, WilkinsonGR, KimRB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos.27(8) , 866–871 (1999).
  • Kullak-Ublick GA , HagenbuchB, StiegerB et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109(4) , 1274–1282 (1995).
  • Glaeser H , BaileyDG, DresserGK et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81(3) , 362–370 (2007).
  • Bailey DG , DresserGK, LeakeBF, KimRB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther.81(4) , 495–502 (2007).
  • Kobayashi D , NozawaT, ImaiK, NezuJ, TsujiA, TamaiI. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther.306(2) , 703–708 (2003).
  • Shimizu M , FuseK, OkudairaK et al. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 33(10) , 1477–1481 (2005).
  • Imanaga J , KotegawaT, ImaiH et al. The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet. Genomics 21(2) , 84–93 (2011).
  • Lilja JJ , BackmanJT, LaitilaJ, LuurilaH, NeuvonenPJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin. Pharmacol. Ther.73(3) , 192–198 (2003).
  • Lilja JJ , Juntti-PatinenL, NeuvonenPJ. Orange juice substantially reduces the bioavailability of the β-adrenergic-blocking agent celiprolol. Clin. Pharmacol. Ther.75(3) , 184–190 (2004).
  • Lilja JJ , RaaskaK, NeuvonenPJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur. J. Clin. Pharmacol.61(5–6) , 337–340 (2005).
  • Neuhofel AL , WiltonJH, VictoryJM, HejmanowskLG, AmsdenGW. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J. Clin. Pharmacol.42(4) , 461–466 (2002).
  • Waldmeier F , GlaenzelU, WirzB et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab. Dispos. 35(8) , 1418–1428 (2007).
  • Vaidyanathan S , JarugulaV, DieterichHA, HowardD, DoleWP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin. Pharmacokinet.47(8) , 515–531 (2008).
  • Tapaninen T , NeuvonenPJ, NiemiM. Orange and apple juices greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br. J. Clin. Pharmacol.71(5) , 718–726 (2011).
  • Vaidyanathan S , CamenischG, SchuetzH et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J. Clin. Pharmacol. 48(11) , 1323–1338 (2008).
  • Buczko W , HermanowiczJM. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol. Rep.60(5) , 623–631 (2008).
  • Tapaninen T , BackmanJT, KurkinenK, NeuvonenPJ, NiemiM. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J. Clin. Pharmacol.51(3) , 359–367 (2011).
  • Tapaninen T , NeuvonenPJ, NiemiM. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur. J. Clin. Pharmacol.66(5) , 497–502 (2010).
  • Tapaninen T , NeuvonenPJ, NiemiM. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin. Pharmacol. Ther.88(3) , 339–342 (2010).
  • Paine MF , CrissAB, WatkinsPB. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J. Pharmacol. Exp. Ther.312(3) , 1151–1160 (2005).
  • Takanaga H , OhnishiA, MatsuoH, SawadaY. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in Caco-2 cells. Biol. Pharm. Bull.21(10) , 1062–1066 (1998).
  • Satoh H , YamashitaF, TsujimotoM et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos. 33(4) , 518–523 (2005).
  • Mandery K , BujokK, SchmidtI et al. Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem. Pharmacol. 80(11) , 1746–1753 (2010).
  • Cascorbi I . P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb. Exp. Pharmacol.201 , 261–283 (2011).
  • Thiebaut F , TsuruoT, HamadaH, GottesmanMM, PastanI, WillinghamMC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA84(21) , 7735–7738 (1987).
  • Igel S , DrescherS, MürdterT et al. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clin. Pharmacokinet. 46(9) , 777–785 (2007).
  • Drescher S , GlaeserH, MürdterT, HitzlM, EichelbaumM, FrommMF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin. Pharmacol. Ther.73(3) , 223–231 (2003).
  • Mouly S , PaineMF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res.20(10) , 1595–1599 (2003).
  • Kolars JC , Schmiedlin-RenP, SchuetzJD, FangC, WatkinsPB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest.90(5) , 1871–1878 (1992).
  • Fromm MF . Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci.25(8) , 423–429 (2004).
  • Benet LZ . The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm.6(6) , 1631–1643 (2009).
  • Lacarelle B , RahmaniR, de Sousa G, Durand A, Placidi M, Cano JP. Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam. Clin. Pharmacol.5(7) , 567–582 (1991).
  • Gheorghiade M , AdamsKF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation109(24) , 2959–2964 (2004).
  • Burk O , BrennerSS, HofmannU et al. The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin. Clin. Pharmacol. Ther. 88(5) , 685–694 (2010).
  • Birkenfeld AL , JordanJ, HofmannU et al. Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. Clin. Pharmacol. Ther. 86(6) , 605–608 (2009).
  • Fenner KS , TroutmanMD, KempshallS et al. Drug–drug interactions mediated through P-glycoprotein: clinical relevance and in vitro–in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther. 85(2) , 173–181 (2009).
  • Giacomini KM , HuangSM, TweedieDJ et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9(3) , 215–236 (2010).
  • Glaeser H . Importance of P-glycoprotein for drug–drug interactions. Handb. Exp. Pharmacol.201 , 285–297 (2011).
  • Greiner B , EichelbaumM, FritzP et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104(2) , 147–153 (1999).
  • Larsen UL , Hyldahl Olesen L, Guldborg Nyvold C et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand. J. Clin. Lab. Invest.67(2) , 123–134 (2007).
  • Gurley BJ , SwainA, WilliamsDK, BaroneG, BattuSK. Gauging the clinical significance of P-glycoprotein-mediated herb–drug interactions: comparative effects of St. John‘s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol. Nutr. Food Res.52(7) , 772–779 (2008).
  • Schinkel AH , MayerU, WagenaarE et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl Acad. Sci. USA 94(8) , 4028–4033 (1997).
  • Reitman ML , ChuX, CaiX et al. Rifampin‘s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug–drug interaction trial design. Clin. Pharmacol. Ther. 89(2) , 234–242 (2011).
  • Fardel O , LecureurV, LoyerP, GuillouzoA. Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem. Pharmacol.49(9) , 1255–1260 (1995).
  • Furusawa S , NakanoS, WuJ, SasakiK, TakayanagiM, TakayanagiY. Potentiation of pirarubicin activity in multidrug resistant cells by rifampicin. Biol. Pharm. Bull.20(12) , 1303–1306 (1997).
  • Westphal K , WeinbrennerA, ZschiescheM et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68(4) , 345–355 (2000).
  • Dürr D , StiegerB, Kullak-UblickGA et al. St John‘s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68(6) , 598–604 (2000).
  • Johne A , BrockmöllerJ, BauerS, MaurerA, LangheinrichM, RootsI. Pharmacokinetic interaction of digoxin with an herbal extract from St John‘s wort (Hypericum perforatum). Clin. Pharmacol. Ther.66(4) , 338–345 (1999).
  • Schwarz UI , HansoH, OertelR et al. Induction of intestinal P-glycoprotein by St John‘s wort reduces the oral bioavailability of talinolol. Clin. Pharmacol. Ther. 81(5) , 669–678 (2007).
  • Leahey EB Jr, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT Jr. Interaction between quinidine and digoxin. JAMA240(6) , 533–534 (1978).
  • Fromm MF , KimRB, SteinCM, WilkinsonGR, RodenDM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation99(4) , 552–557 (1999).
  • Eberl S , RennerB, NeubertA et al. Role of P-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin. Pharmacokinet. 46(12) , 1039–1049 (2007).
  • Hughes J , CroweA. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J. Pharmacol. Sci.113(4) , 315–324 (2010).
  • Rengelshausen J , GoggelmannC, BurhenneJ et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br. J. Clin. Pharmacol. 56(1) , 32–38 (2003).
  • Jonker JW , SmitJW, BrinkhuisRF et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl Cancer Inst. 92(20) , 1651–1656 (2000).
  • Kruijtzer CM , BeijnenJH, RosingH et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20(13) , 2943–2950 (2002).
  • Wynne HA , CopeLH, MutchE, RawlinsMD, WoodhouseKW, JamesOF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology9(2) , 297–301 (1989).
  • Yzet T , BouzerarR, AllartJD et al. Hepatic vascular flow measurements by phase contrast MRI and doppler echography: a comparative and reproducibility study. J. Magn. Reson. Imaging 31(3) , 579–588 (2010).
  • Omori S , IshizakiY, SugoH et al. Direct measurement of hepatic blood flow during living donor liver transplantation in children. J. Pediatr. Surg. 45(3) , 545–548 (2010).
  • Walser EM , DeLa Pena R, Villanueva-Meyer J, Ozkan O, Soloway R. Hepatic perfusion before and after the transjugular intrahepatic portosystemic shunt procedure: impact on survival. J. Vasc. Interv. Radiol.11(7) , 913–918 (2000).
  • Zhong L , WangWJ, XuJR. Clinical application of hepatic CT perfusion. World J. Gastroenterol.15(8) , 907–911 (2009).
  • Kulik A , BrookhartMA, LevinR, RuelM, SolomonDH, ChoudhryNK. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation118(18) , 1785–1792 (2008).
  • Ballantyne CM , RaichlenJS, NichollsSJ et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 117(19) , 2458–2466 (2008).
  • Berriche O , AmroucheC, JamoussiH, BlouzaS. Efficacy and safety of statins in the treatment of diabetic dyslipidemia. Tunis. Med.88(2) , 80–84 (2010).
  • Stein EA , AmerenaJ, BallantyneCM et al. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am. J. Cardiol. 100(9) , 1387–1396 (2007).
  • Hippisley -Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ340 , c2197 (2010).
  • Graham DJ , StaffaJA, ShatinD et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292(21) , 2585–2590 (2004).
  • Hedenmalm K , AlvanG, ÖhagenP, DahlML. Muscle toxicity with statins. Pharmacoepidemiol. Drug Saf.19(3) , 223–231 (2010).
  • Keskitalo JE , KurkinenKJ, NeuvonenM, BackmanJT, NeuvonenPJ, NiemiM. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br. J. Clin. Pharmacol.68(2) , 207–213 (2009).
  • Neuvonen PJ . Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr. Opin. Investig. Drugs11(3) , 323–332 (2010).
  • K önig J. Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug–drug interactions, and functional consequences of polymorphisms. Handb. Exp. Pharmacol.201 , 1–28 (2011).
  • Voora D , ShahSH, SpasojevicI et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54(17) , 1609–1616 (2009).
  • Link E , ParishS, ArmitageJ et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med.359(8) , 789–799 (2008).
  • Pasanen MK , NeuvonenM, NeuvonenPJ, NiemiM. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics16(12) , 873–879 (2006).
  • Peters BJ , RodinAS, KlungelOH et al. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics 11(8) , 1065–1076 (2010).
  • Niemi M , PasanenMK, NeuvonenPJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev.63(1) , 157–181 (2011).
  • Seithel A , EberlS, SingerK et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos. 35(5) , 779–786 (2007).
  • Kitamura S , MaedaK, WangY, SugiyamaY. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos.36(10) , 2014–2023 (2008).
  • Ho RH , TironaRG, LeakeBF et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130(6) , 1793–1806 (2006).
  • Shirasaka Y , SuzukiK, NakanishiT, TamaiI. Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide. Pharm. Res.27(10) , 1241–2149 (2010).
  • Choi MK , ShinHJ, ChoiYL, DengJW, ShinJG, SongIS. Differential effect of genetic variants of Na+-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica41(1) , 24–34 (2011).
  • Dawson PA , LanT, RaoA. Bile acid transporters. J. Lipid. Res.50(12) , 2340–2357 (2009).
  • Nakagomi-Hagihara R , NakaiD, TokuiT, AbeT, IkedaT. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica37(5) , 474–486 (2007).
  • Hirano M , MaedaK, ShitaraY, SugiyamaY. Drug–drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos.34(7) , 1229–1236 (2006).
  • Noé J , PortmannR, BrunME, FunkC. Substrate-dependent drug–drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos.35(8) , 1308–1314 (2007).
  • Kyrklund C , BackmanJT, NeuvonenM, NeuvonenPJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther.73(6) , 538–544 (2003).
  • Schneck DW , BirminghamBK, ZalikowskiJA et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75(5) , 455–463 (2004).
  • Bergman E , MatssonEM, HedelandM, BondessonU, KnutsonL, LennernäsH. Effect of a single gemfibrozil dose on the pharmacokinetics of rosuvastatin in bile and plasma in healthy volunteers. J. Clin. Pharmacol.50(9) , 1039–1049 (2010).
  • Backman JT , KyrklundC, KivistöKT, WangJS, NeuvonenPJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther.68(2) , 122–129 (2000).
  • Whitfield LR , PorcariAR, AlveyC, AbelR, BullenW, HartmanD. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J. Clin. Pharmacol.51(3) , 378–388 (2011).
  • Backman JT , KyrklundC, NeuvonenM, NeuvonenPJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther.72(6) , 685–691 (2002).
  • Staffa JA , ChangJ, GreenL. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med.346(7) , 539–540 (2002).
  • Wang JS , NeuvonenM, WenX, BackmanJT, NeuvonenPJ. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos.30(12) , 1352–1356 (2002).
  • Shitara Y , HiranoM, SatoH, SugiyamaY. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther.311(1) , 228–236 (2004).
  • Hermann M , ÅsbergA, ChristensenH, HoldaasH, HartmannA, ReubsaetJL. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin. Pharmacol. Ther.76(4) , 388–391 (2004).
  • Olbricht C , WannerC, EisenhauerT et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin. Pharmacol. Ther. 62(3) , 311–321 (1997).
  • Park JW , SiekmeierR, MerzM et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int. J. Clin. Pharmacol. Ther. 40(10) , 439–450 (2002).
  • Hedman M , NeuvonenPJ, NeuvonenM, HolmbergC, AntikainenM. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin. Pharmacol. Ther.75(1) , 101–109 (2004).
  • Lasocki A , VoteB, FassettR, ZamirE. Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis. Ocul. Immunol. Inflamm.15(4) , 345–346 (2007).
  • Tong J , LaportG, LowskyR. Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Bone Marrow Transplant36(8) , 739–740 (2005).
  • Wong WM , Wai-Hung Shek T, Chan KH, Chau E, Lai KC. Rhabdomyolysis triggered by cytomegalovirus infection in a heart transplant patient on concomitant cyclosporine and atorvastatin therapy. J. Gastroenterol. Hepatol.19(8) , 952–953 (2004).
  • Maltz HC , BalogDL, CheighJS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann. Pharmacother.33(11) , 1176–1179 (1999).
  • Rifkin SI . Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report. Medscape J. Med.10(11) , 264 (2008).
  • Schreiber DH , AndersonTR. Statin-induced rhabdomyolysis. J. Emerg. Med.31(2) , 177–180 (2006).
  • Chu XY , BleasbyK, YabutJ et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J. Pharmacol. Exp. Ther. 321(2) , 673–683 (2007).
  • Kamisako T , LeierI, CuiY et al. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 30(2) , 485–490 (1999).
  • Niwa T , YamamotoS, SaitoM, ShiragaT, TakagiA. Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. Yakugaku Zasshi127(1) , 209–216 (2007).
  • Haehner T , RefaieMO, Müller-EnochD. Drug–drug interactions evaluated by a highly active reconstituted native human cytochrome P4503A4 and human NADPH-cytochrome P450 reductase system. Arzneimittelforschung54(1) , 78–83 (2004).
  • Simonson SG , RazaA, MartinPD et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76(2) , 167–177 (2004).
  • Bergman E , LundahlA, FridblomP et al. Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. Drug Metab. Dispos. 37(12) , 2349–2358 (2009).
  • Klotz U , AntoninKH. Biliary excretion studies with digoxin in man. Int J. Clin. Pharmacol. Biopharm.15(7) , 332–334 (1977).
  • Hedman A , AngelinB, ArvidssonA, DahlqvistR, NilssonB. Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin. Pharmacol. Ther.47(1) , 20–26 (1990).
  • Angelin B , ArvidssonA, DahlqvistR, HedmanA, Schenck-GustafssonK. Quinidine reduces biliary clearance of digoxin in man. Eur. J. Clin. Invest.17(3) , 262–265 (1987).
  • Hedman A , AngelinB, ArvidssonA et al. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin. Pharmacol. Ther. 49(3) , 256–262 (1991).
  • Suzuyama N , KatohM, TakeuchiT et al. Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. J. Pharm. Sci. 96(6) , 1609–1618 (2007).
  • Wang EJ , LewK, CascianoCN, ClementRP, JohnsonWW. Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother.46(1) , 160–165 (2002).
  • Nishihara K , HibinoJ, KotakiH, SawadaY, IgaT. Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. Biopharm. Drug Dispos.20(3) , 145–149 (1999).
  • Funakoshi S , MurakamiT, YumotoR, KiribayashiY, TakanoM. Role of P-glycoprotein in pharmacokinetics and drug interactions of digoxin and β-methyldigoxin in rats. J. Pharm. Sci.92(7) , 1455–1463 (2003).
  • Koren G , KleinJ, GiesbrechtE et al. Effects of quinidine on the renal tubular and biliary transport of digoxin: in vivo and in vitro studies in the dog. J. Pharmacol. Exp. Ther. 247(3) , 1193–1198 (1988).
  • Ben-Itzhak J , BassanHM, ShorR, LanirA. Digoxin quinidine interaction: a pharmacokinetic study in the isolated perfused rat liver. Life Sci.37(5) , 411–415 (1985).
  • Hewick DS , OstenfeldT. The effect of digoxin dosage on the digoxin-quinidine interaction in the bile duct-cannulated rat. J. Pharm. Pharmacol.39(1) , 64–67 (1987).
  • Lau YY , WuCY, OkochiH, BenetLZ. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J. Pharmacol. Exp. Ther.308(3) , 1040–1045 (2004).
  • Hedman A , MeijerDK. Stereoselective inhibition by the diastereomers quinidine and quinine of uptake of cardiac glycosides into isolated rat hepatocytes. J. Pharm. Sci.87(4) , 457–461 (1998).
  • Olinga P , MeremaM, HofIH et al. Characterization of the uptake of rocuronium and digoxin in human hepatocytes: carrier specificity and comparison with in vivo data. J. Pharmacol. Exp. Ther. 285(2) , 506–510 (1998).
  • Otsuka M , MatsumotoT, MorimotoR, AriokaS, OmoteH, MoriyamaY. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl Acad. Sci. USA102(50) , 17923–17928 (2005).
  • Nies AT , KoepsellH, DammeK, SchwabM. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb. Exp. Pharmacol.201 , 105–167 (2011).
  • Ito S , KusuharaH, KuroiwaY et al. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J. Pharmacol. Exp. Ther. 333(1) , 341–350 (2010).
  • Tsuda M , TeradaT, MizunoT, KatsuraT, ShimakuraJ, InuiK. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol. Pharmacol.75(6) , 1280–1286 (2009).
  • Russmann S , JetterA, Kullak-UblickGA. Pharmacogenetics of drug-induced liver injury. Hepatology52(2) , 748–761 (2010).
  • Zolk O , FrommMF. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin. Pharmacol. Ther.89(6) , 798–805 (2011).
  • Burckhardt G , BurckhardtBC. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb. Exp. Pharmacol.201 , 29–104 (2011).
  • Overbosch D , Van Gulpen C, Hermans J, Mattie H. The effect of probenecid on the renal tubular excretion of benzylpenicillin. Br. J. Clin. Pharmacol.25(1) , 51–58 (1988).
  • Tahara H , ShonoM, KusuharaH et al. Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharm. Res. 22(4) , 647–660 (2005).
  • Nozaki Y , KusuharaH, KondoT et al. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther. 322(3) , 1162–1170 (2007).
  • Cihlar T , HoES. Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal. Biochem.283(1) , 49–55 (2000).
  • Mulato AS , HoES, CihlarT. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J. Pharmacol. Exp. Ther.295(1) , 10–15 (2000).
  • Jung KY , TakedaM, KimDK et al. Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 69(18) , 2123–2135 (2001).
  • Khamdang S , TakedaM, ShimodaM et al. Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J. Pharmacol. Sci. 94(2) , 197–202 (2004).
  • Hashimoto T , NarikawaS, HuangXL et al. Characterization of the renal tubular transport of zonampanel, a novel α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters. Drug Metab. Dispos. 32(10) , 1096–1102 (2004).
  • Odlind B , BeermannB. Renal tubular secretion and effects of furosemide. Clin. Pharmacol. Ther.27(6) , 784–790 (1980).
  • Vree TB , van den Biggelaar-Martea M, Verwey-van Wissen CP. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br. J. Clin. Pharmacol.39(6) , 692–695 (1995).
  • Smith DE , GeeWL, BraterDC, LinET, BenetLZ. Preliminary evaluation of furosemide-probenecid interaction in humans. J. Pharm. Sci.69(5) , 571–575 (1980).
  • Aherne GW , MarksV, MouldGP, PiallE, WhiteWF. The interaction between methotrexate and probenecid in man. Br. J. Pharmacol.63(2) , 369P (1978).
  • Nakagomi-Hagihara R , NakaiD, TokuiT. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica37(4) , 416–426 (2007).
  • Takeda M , NoshiroR, OnozatoML et al. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur. J. Pharmacol. 483(2–3) , 133–138 (2004).
  • Lalezari JP , DrewWL, GlutzerE et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171(4) , 788–796 (1995).
  • Ortiz A , JustoP, SanzA et al. Tubular cell apoptosis and cidofovir-induced acute renal failure. Antivir. Ther. 10(1) , 185–190 (2005).
  • Izzedine H , Launay-VacherV, DerayG. Antiviral drug-induced nephrotoxicity. Am. J. Kidney Dis.45(5) , 804–817 (2005).
  • Ho ES , LinDC, MendelDB, CihlarT. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol.11(3) , 383–393 (2000).
  • Cihlar T , LinDC, PritchardJB, FullerMD, MendelDB, SweetDH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol.56(3) , 570–580 (1999).
  • Uwai Y , IdaH, TsujiY, KatsuraT, InuiK. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res.24(4) , 811–815 (2007).
  • Lacy SA , HitchcockMJ, LeeWA, TellierP, CundyKC. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol. Sci.44(2) , 97–106 (1998).
  • Cundy KC , LiZH, LeeWA. Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. Drug Metab. Dispos.24(3) , 315–321 (1996).
  • Cundy KC , PettyBG, FlahertyJ et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39(6) , 1247–1252 (1995).
  • Cesaro S , ZhouX, ManzardoC et al. Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation. J. Clin. Virol. 34(2) , 129–132 (2005).
  • Yusuf U , HaleGA, CarrJ et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 81(10) , 1398–1404 (2006).
  • Busch AE , KarbachU, MiskaD et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol. Pharmacol. 54(2) , 342–352 (1998).
  • Tahara H , KusuharaH, EndouH et al. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther. 315(1) , 337–345 (2005).
  • Kimura N , OkudaM, InuiK. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm. Res.22(2) , 255–259 (2005).
  • Jung N , LehmannC, RubbertA et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab. Dispos. 36(8) , 1616–1623 (2008).
  • Minuesa G , VolkC, Molina-ArcasM et al. Transport of lamivudine [(-)-β-L-2‘,3‘-dideoxy-3‘-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J. Pharmacol. Exp. Ther. 329(1) , 252–261 (2009).
  • Somogyi A , StockleyC, KealJ, RolanP, BochnerF. Reduction of metformin renal tubular secretion by cimetidine in man. Br. J. Clin. Pharmacol.23(5) , 545–551 (1987).
  • van Crugten J , BochnerF, KealJ, SomogyiA. Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. J. Pharmacol. Exp. Ther.236(2) , 481–487 (1986).
  • Feng B , ObachRS, BursteinAH, ClarkDJ, de Morais SM, Faessel HM. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin. Pharmacol. Ther.83(4) , 567–576 (2008).
  • de Jongh FE , van Veen RN, Veltman SJ et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer88(8) , 1199–1206 (2003).
  • Máthé C , BohácsA, DuffekL et al. Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur. Respir. J. 37(4) , 888–894 (2011).
  • Pabla N , DongZ. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int.73(9) , 994–1007 (2008).
  • Rabik CA , DolanME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev.33(1) , 9–23 (2007).
  • Ciarimboli G , LudwigT, LangD et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 167(6) , 1477–1484 (2005).
  • Yonezawa A , MasudaS, YokooS, KatsuraT, InuiK. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1–3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther.319(2) , 879–886 (2006).
  • Burger H , Zoumaro-DjayoonA, BoersmaAW et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br. J. Pharmacol. 159(4) , 898–908 (2010).
  • Filipski KK , LoosWJ, VerweijJ, SparreboomA. Interaction of cisplatin with the human organic cation transporter 2. Clin. Cancer Res.14(12) , 3875–3880 (2008).
  • Ciarimboli G , DeusterD, KniefA et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 176(3) , 1169–1180 (2010).
  • Franke RM , KosloskeAM, LancasterCS et al. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-β-d-glucosaminidase. Clin. Cancer Res. 16(16) , 4198–4206 (2010).
  • Filipski KK , MathijssenRH, MikkelsenTS, SchinkelAH, SparreboomA. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther.86(4) , 396–402 (2009).
  • Yonezawa A , InuiKI. Organic cation transporter OCT/SLC22A and H+/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem. Pharmacol.81(5) , 563–568 (2010).
  • Katsuda H , YamashitaM, KatsuraH et al. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol. Pharm. Bull. 33(11) , 1867–1871 (2010).
  • Ludwig T , RiethmüllerC, GekleM, SchwerdtG, OberleithnerH. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int.66(1) , 196–202 (2004).
  • Tanihara Y , MasudaS, KatsuraT, InuiK. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem. Pharmacol.78(9) , 1263–1271 (2009).
  • Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am. J. Physiol. Renal Physiol.298(4) , F997-F1005 (2010).
  • Tanihara Y , MasudaS, SatoT, KatsuraT, OgawaO, InuiK. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. Biochem. Pharmacol.74(2) , 359–371 (2007).
  • König J , ZolkO, SingerK, HoffmannC, FrommMF. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br. J. Pharmacol.163(3) , 546–555 (2011).
  • Kimura N , MasudaS, TaniharaY et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet. 20(5) , 379–386 (2005).
  • Terada T , InuiK. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochem. Pharmacol.75(9) , 1689–1696 (2008).
  • Sato T , MasudaS, YonezawaA, TaniharaY, KatsuraT, InuiK. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem. Pharmacol.76(7) , 894–903 (2008).
  • Tsuda M , TeradaT, UebaM et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J. Pharmacol. Exp. Ther. 329(1) , 185–191 (2009).
  • Umehara KI , IwatsuboT, NoguchiK, UsuiT, KamimuraH. Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1–3 in vitro and implications for drug–drug interactions. Xenobiotica38(9) , 1203–1218 (2008).
  • Pedersen KE , HastrupJ, HvidtS. The effect of quinidine on digoxin kinetics in cardiac patients. Acta Med. Scand.207(4) , 291–295 (1980).
  • Dahlqvist R , EjvinssonG, Schenck-GustafssonK. Effect of quinidine on plasma concentration and renal clearance of digoxin. A clinically important drug interaction. Br. J. Clin. Pharmacol.9(4) , 413–418 (1980).
  • Schenck-Gustafsson K , DahlqvistR. Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. Br. J. Clin. Pharmacol.11(2) , 181–186 (1981).
  • Ochs HR , BodemG, GreenblattDJ. Impairment of digoxin clearance by coadministration of quinidine. J. Clin. Pharmacol.21(10) , 396–400 (1981).
  • Ding R , TayrouzY, RiedelKD et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 76(1) , 73–84 (2004).
  • Jalava KM , PartanenJ, NeuvonenPJ. Itraconazole decreases renal clearance of digoxin. Ther. Drug Monit.19(6) , 609–613 (1997).
  • Huls M , BrownCD, WindassAS et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int. 73(2) , 220–225 (2008).
  • Vlaming ML , PalaZ, van Esch A et al. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin. Cancer Res.15(9) , 3084–3093 (2009).
  • Woodward OM , KöttgenA, CoreshJ, BoerwinkleE, GugginoWB, KöttgenM. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl Acad. Sci. USA106(25) , 10338–10342 (2009).
  • Dehghan A , KöttgenA, YangQ et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372(9654) , 1953–1961 (2008).
  • Kolz M , JohnsonT, SannaS et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 5(6) , e1000504 (2009).
  • Stark K , ReinhardW, GrasslM et al. Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS ONE 4(11) , e7729 (2009).
  • Wang B , MiaoZ, LiuS et al. Genetic analysis of ABCG2 gene C421A polymorphism with gout disease in Chinese Han male population. Hum. Genet. 127(2) , 245–246 (2010).
  • Br⊘sen K , HansenJG, NielsenKK, SindrupSH, GramLF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur. J. Clin. Pharmacol.44(4) , 349–355 (1993).
  • Yasui-Furukori N , SaitoM, UnoT, TakahataT, SugawaraK, TateishiT. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J. Clin. Pharmacol.44(11) , 1223–1229 (2004).
  • Kajosaari LI , NiemiM, NeuvonenM, LaitilaJ, NeuvonenPJ, BackmanJT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther.78(4) , 388–399 (2005).
  • Wang ZJ , YinOQ, TomlinsonB, ChowMS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet. Genomics18(7) , 637–645 (2008).
  • Zolk O , SolbachTF, KönigJ, FrommMF. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab. Dispos.37(6) , 1312–1318 (2009).
  • Nozawa T , NakajimaM, TamaiI et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302(2) , 804–813 (2002).
  • Kato Y , MiyazakiT, KanoT, SugiuraT, KuboY, TsujiA. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J. Pharm. Sci.98(7) , 2529–2539 (2009).
  • Maeda T , TakahashiK, OhtsuN et al. Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol. Pharm. 4(1) , 85–94 (2007).
  • Lee W , GlaeserH, SmithLH et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 280(10) , 9610–9617 (2005).
  • Gao B , HuberRD, WenzelA et al. Localization of organic anion transporting polypeptides in the rat and human ciliary body epithelium. Exp. Eye Res. 80(1) , 61–72 (2005).
  • Kullak-Ublick GA , IsmairMG, StiegerB et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120(2) , 525–533 (2001).
  • Niessen J , JedlitschkyG, GrubeM et al. Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab. Dispos. 37(5) , 1129–1137 (2009).
  • Grube M , KöckK, OswaldS et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther. 80(6) , 607–620 (2006).
  • Grube M , ReutherS, Meyer zu Schwabedissen H et al. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta. Drug Metab. Dispos.35(1) , 30–35 (2007).
  • Shirasaka Y , SuzukiK, ShichiriM, NakanishiT, TamaiI. Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. Drug Metab. Pharmacokinet.26(2) , 171–179 (2011).
  • Kraft ME , GlaeserH, ManderyK et al. The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest. Ophthalmol. Vis. Sci. 51(5) , 2504–2511 (2010).
  • König J , CuiY, NiesAT, KepplerD. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver. Physiol.278(1) , G156–G164 (2000).
  • Annaert P , YeZW, StiegerB, AugustijnsP. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica40(3) , 163–176 (2010).
  • Treiber A , SchneiterR, HäuslerS, StiegerB. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Dispos.35(8) , 1400–1407 (2007).
  • Vavricka SR , Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology36(1) , 164–172 (2002).
  • Yamashiro W , MaedaK, HirouchiM, AdachiY, HuZ, SugiyamaY. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab. Dispos.34(7) , 1247–1254 (2006).
  • König J , CuiY, NiesAT, KepplerD. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem.275(30) , 23161–23168 (2000).
  • Smith NF , AcharyaMR, DesaiN, FiggWD, SparreboomA. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol. Ther.4(8) , 815–818 (2005).
  • Motohashi H , SakuraiY, SaitoH et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 13(4) , 866–874 (2002).
  • Hilgendorf C , AhlinG, SeithelA, ArturssonP, UngellAL, KarlssonJ. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos.35(8) , 1333–1340 (2007).
  • Nishimura M , NaitoS. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab. Pharmacokinet.20(6) , 452–477 (2005).
  • Hasannejad H , TakedaM, TakiK et al. Interactions of human organic anion transporters with diuretics. J. Pharmacol. Exp. Ther. 308(3) , 1021–1029 (2004).
  • Uwai Y , MotohashiH, TsujiY, UeoH, KatsuraT, InuiK. Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem. Pharmacol.74(1) , 161–168 (2007).
  • Khamdang S , TakedaM, NoshiroR et al. Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 303(2) , 534–539 (2002).
  • Sato M , IwanagaT, MamadaH et al. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm. Res. 25(3) , 639–646 (2008).
  • Ueo H , MotohashiH, KatsuraT, InuiK. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem. Pharmacol.70(7) , 1104–1113 (2005).
  • Cha SH , SekineT, FukushimaJI et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. 59(5) , 1277–1286 (2001).
  • Yamada A , MaedaK, KamiyamaE et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab. Dispos. 35(12) , 2166–2176 (2007).
  • Nies AT , HerrmannE, BromM, KepplerD. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch. Pharmacol.376(6) , 449–461 (2008).
  • Lips KS , VolkC, SchmittBM et al. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am. J. Respir. Cell. Mol. Biol. 33(1) , 79–88 (2005).
  • Taubert D , GrimbergG, StenzelW, SchömigE. Identification of the endogenous key substrates of the human organic cation transporter OCT2 and their implication in function of dopaminergic neurons. PLoS ONE2(4) , e385 (2007).
  • Bachmakov I , GlaeserH, EndressB, MörlF, KönigJ, FrommMF. Interaction of beta-blockers with the renal uptake transporter OCT2. Diabetes Obes. Metab.11(11) , 1080–1083 (2009).
  • Zolk O , SolbachTF, KönigJ, FrommMF. Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch. Pharmacol.379(4) , 337–348 (2009).
  • Minematsu T , IwaiM, UmeharaK, UsuiT, KamimuraH. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab. Dispos.38(1) , 1–4 (2010).
  • Masuda S , TeradaT, YonezawaA et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 17(8) , 2127–2135 (2006).
  • Ohta KY , InoueK, YasujimaT, IshimaruM, YuasaH. Functional characteristics of two human MATE transporters: kinetics of cimetidine transport and profiles of inhibition by various compounds. J. Pharm. Pharm. Sci.12(3) , 388–396 (2009).
  • Watanabe S , TsudaM, TeradaT, KatsuraT, InuiK. Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J. Pharmacol. Exp. Ther.334(2) , 651–656 (2010).
  • Tanigawara Y , OkamuraN, HiraiM et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. 263(2) , 840–845 (1992).
  • Wils P , Phung-BaV, WarneryA et al. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol. 48(7) , 1528–1530 (1994).
  • Lee CG , GottesmanMM, CardarelliCO et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37(11) , 3594–3601 (1998).
  • Goldberg H , LingV, WongPY, SkoreckiK. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem. Biophys. Res. Commun.152(2) , 552–558 (1988).
  • Anderle P , NiedererE, RubasW et al. P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J. Pharm. Sci. 87(6) , 757–762 (1998).
  • Drewe J , GutmannH, FrickerG, TörökM, BeglingerC, HuwylerJ. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol.57(10) , 1147–1152 (1999).
  • Sugawara I , KataokaI, MorishitaY et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 48(7) , 1926–1929 (1988).
  • Cordon-Cardo C , O‘BrienJP, CasalsD et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc. Natl Acad. Sci. USA 86(2) , 695–698 (1989).
  • Abel S , NicholsDJ, BrearleyCJ, EveMD. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br. J. Clin. Pharmacol.49(1) , 64–71 (2000).
  • Somogyi AA , BochnerF, SallustioBC. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin. Pharmacol. Ther.51(4) , 379–387 (1992).
  • Kosoglou T , RocciML Jr, Vlasses PH. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. Clin. Pharmacol. Ther.44(4) , 467–477 (1988).
  • Fenster PE , HagerWD, PerrierD, PowellJR, GravesPE, MichaelUF. Digoxin-quinidine interaction in patients with chronic renal failure. Circulation66(6) , 1277–1280 (1982).
  • Leahey EB Jr, Bigger JT Jr, Butler VP Jr et al. Quinidine-digoxin interaction: time course and pharmacokinetics. Am. J. Cardiol.48(6) , 1141–1146 (1981).
  • Fenster PE , HagerWD, GoodmanMM. Digoxin-quinidine-spironolactone interaction. Clin. Pharmacol. Ther.36(1) , 70–73 (1984).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.